JPRN-UMIN000046456
Recruiting
未知
Clinical efficacy study of neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for resectable pancreatic cancer - NAC-IMRT for resectable pancreatic cancer
Conditionspancreatic cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- pancreatic cancer
- Sponsor
- Kyoto Katsura Hospital
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Performance status: 2\-4 (according to ECOG criteria) 2\.Difficulty in oral intake 3\.Severe hepatic or renal impairment 4\.Active infectious disease 5\.History of radiation therapy for abdominal organs 6\.In case the attending physician deems it inappropriate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II studyColon cancerJPRN-UMIN000006742Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group195
Recruiting
Phase 2
The Efficacy and Feasibility Study of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer (Est-Neo)Rectal CancerJPRN-UMIN000005654Gastro-intestinal Sugery Division, Kyoto University Hospital55
Active, not recruiting
Phase 1
eoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)Patients with very high-risk prostate cancer (as defined by a total Gleason-Score =4+4 [ISUP-GG 4+5] and clinical stage cT3 (digital rectal examinations or imaging based) plus clinical nodal status cN+ or Serum-PSA level > 20 ng/ml who are candidates for radical prostatectomy with pelvic lymph node dissection.Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]CTIS2024-514386-19-00niversitaetsklinikum Essen AöR58
Completed
Not Applicable
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies.Salivary gland tumorJPRN-UMIN000024669Chiba University Hospital6
Completed
Phase 1
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with high-grade salivary grand tumor followed by standard therpies.High-grade salivary grand tumorJPRN-UMIN000011509Department of Otorynolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University9